NovMetaPharma Co., Ltd. (XKON:229500)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,200.00
+400.00 (5.88%)
At close: Jul 20, 2026
Market Cap78.59B -43.6%
Revenue (ttm)1.30B +21.4%
Net Income408.03M
EPS120.00
Shares Out 12.84M
PE Ratio51.00
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,181
Open6,990.00
Previous Close6,800.00
Day's Range6,230.00 - 7,200.00
52-Week Range5,850.00 - 17,890.00
Beta0.16
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NovMetaPharma

NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea. It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD. It has a clinical development and licensing collaboration with the FSHD Canada Foundation to advance Cyclo-Z, NMP’s lead oral CLIC1 conformational modulator, as a treatment for facioscapulohumeral muscular dystrophy. The... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 229500
Full Company Profile